Product Structure - The company's products are mainly divided into two categories: medical devices and functional skincare products [2] - Non-patch products include various forms such as water, essence, lotion, spray, lyophilized, and single-use essence [2] Non-Patch Product Revenue - The revenue share of non-patch products is continuously increasing following the establishment of the Shanghai R&D center, which has accelerated the speed of new product launches [2] Medical Device Progress - The company is making significant progress with three types of medical devices, including recombinant type III humanized collagen protein lyophilized fibers and dressings, with clinical trials completed for the former [3] - The injectable recombinant type III humanized collagen protein gel is expected to start clinical trials this year [3] Pricing Stability - The pricing situation for the company's products is stable, with overall price differences across channels being controllable [3] - Price fluctuations among mainstream channels remain within a reasonable range, with promotional strategies employed to balance sales and pricing during peak periods [3] Aesthetic Medicine Strategy - The company is strategically entering the aesthetic medicine sector due to its pharmaceutical background, aligning medical device products with existing offerings [3] - The company is monitoring potential acquisition targets in the aesthetic medicine field and will adhere to regulatory disclosure obligations for any developments [3] Dividend Policy - The company has maintained a positive attitude towards returning profits to investors through cash dividends since its listing, although specific dividend amounts will depend on performance and financial planning [3] Equity Incentives - The company has plans for equity incentives as the management team evolves, with intentions to disclose specific details in future announcements [3]
敷尔佳(301371) - 2026年2月27日投资者关系活动记录表